James Huang - 18 Mar 2026 Form 3 Insider Report for CASI Pharmaceuticals, Inc. (CASIF)

Reporting relationship: Director
Issuer ticker: CASIF
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 16:30:37 UTC
Prior SEC filing: 08 Jun 2023
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ James Huang

Key filing fact

James Huang filed Form 3 for CASI Pharmaceuticals, Inc. (CASIF) on 18 Mar 2026.

Key facts

This page summarizes James Huang's Form 3 filing for CASI Pharmaceuticals, Inc. (CASIF).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 08 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001573160 Primary reporting owner

Huang James

Relationship: Director
Address: C/O PANACEA VENTURE, NO. 5, LANE 1350, FUXING MIDDLE ROAD, SHANGHAI, CHINA
Signature: /s/ James Huang
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CASIF holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,529,956
Date: 18 Mar 2026
Ownership: See Footnote
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CASIF holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,000
Exercise price: $1.69
Footnotes: F2

CASIF holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,000
Exercise price: $2.69
Footnotes: F2

CASIF holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 101,571
Exercise price: $1.93
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, James Huang may be deemed to share beneficial ownership of the Ordinary Shares reported herein, but disclaims such beneficial ownership.

Footnote F2

The stock option is fully vested and exercisable.